According to a report by Intel Market Research, the global Montelukast Sodium API Market was valued at USD 96.0 million in 2025 and is estimated to reach USD 98.6 million in 2026. The market is projected to reach USD 126.0 million by 2034, representing a CAGR of 3.1% during 2026–2034. Montelukast sodium is a mature oral respiratory API used in asthma maintenance, prevention of exercise-induced bronchoconstriction, and allergic rhinitis. The market is supported by broad generic availability, pediatric and adult dosage forms, and once-daily oral administration.

Explore the full report: https://www.intelmarketresearch.com/montelukast-sodium-api-64496

Why Is Demand Increasing?

• A large asthma treatment base: WHO reported 363 million people living with asthma worldwide in 2023, creating a substantial long-term respiratory treatment population in which montelukast retains an established role.

• Recurring generic utilization: An ASPE/CMS analysis documented more than 2.54 million generic 30-day-equivalent montelukast prescriptions in a 2022 Medicare employer-group waiver-plan cohort, demonstrating substantial generic utilization.

• Regulatory-file breadth and supply qualification: Customers continue to value suppliers with broad regulatory packages. Dr. Reddy's has listed U.S., European, Canadian, Chinese, Japanese and other filings, while its disclosed Japan and Benin DMF activity illustrates how geographic regulatory expansion can support additional commercial opportunities.

Pharmaceutical API & Respiratory Treatment Watch

The Montelukast Sodium API industry is being shaped by mature generic economics, established respiratory applications and increasing attention to supplier qualification. Although the molecule remains an established oral option, finished-dose pricing is highly competitive, placing pressure on API manufacturers to control synthesis costs, yields, impurities and supply continuity.

Safety considerations are also influencing the demand environment. The report notes that the FDA requires a boxed warning for montelukast because of serious neuropsychiatric risks and advises restricting its use for allergic rhinitis when alternatives are effective and tolerated. This makes asthma and selected respiratory applications more important to the market outlook while limiting the potential for unrestricted allergy-led expansion.

At the supply level, regulatory documentation, manufacturing consistency and geographic reach remain important. India is particularly significant to merchant API supply, while China also participates in the broader API manufacturing base. Suppliers with multi-market regulatory files and the ability to support different dosage-form requirements can address a wider formulation customer base.

Segmentation Highlights

• By Supply Type: The market covers Merchant API and Captive API. Merchant API represents the principal commercial supply model, as generic and consumer-health formulators commonly qualify specialized external API manufacturers.

• Merchant API: Buyers prioritize regulatory files, pharmacopeial compliance, impurity control, change-management discipline and reliable lead times. Dual sourcing across geographies is also becoming increasingly relevant to supply resilience.

• Captive API: Vertically integrated production remains relevant where pharmaceutical companies manufacture montelukast sodium for their own finished-dose portfolios or strategic regional supply.

• By Application: The market is segmented into Asthma Maintenance, Exercise-Induced Bronchoconstriction and Allergic Rhinitis.

• Leading Application: Asthma Maintenance represents the principal demand pool, supported by established medicine use and recurring generic procurement.

Regional Outlook

• North America: North America held the leading value position in 2025, supported by regulated-market medicine utilization, established generic channels and demanding supplier-qualification standards.

• United States: The CDC reported 27.807 million people with current asthma in the United States in 2023. At the same time, FDA safety requirements influence montelukast's use in allergy treatment.

• Europe: Europe represents a mature regulated market characterized by established generic utilization, national reimbursement systems and strong requirements around GMP, impurity control and regulatory documentation.

• Asia-Pacific: Asia-Pacific combines significant medicine demand with the deepest global base of generic API manufacturing. India and China are central to regulated-market supply, while Japan, South Korea and Australia contribute demand.

• Latin America: The region represents a smaller but durable market supported by generic medicine programs, private retail channels and regional formulation manufacturers.

• Middle East & Africa: The region offers longer-term volume opportunities as medicine access, public procurement and local formulation capacity expand, although affordability and country-specific registration requirements influence demand.

Download the free sample report: https://www.intelmarketresearch.com/download-free-sample/64496/montelukast-sodium-api

Why This Market Matters

Montelukast Sodium API remains a durable component of the generic respiratory pharmaceutical supply chain. Its established use in asthma maintenance, exercise-induced bronchoconstriction and allergic rhinitis creates demand across multiple application groups, while tablets, chewable tablets and granules support adult and pediatric formulations.

For API manufacturers, however, commercial opportunity is closely connected to supply quality and regulatory readiness. The report highlights impurity control, polymorphic consistency, granular-grade capability, multi-market DMFs and reliable supply as important factors for competing in regulated markets. Mature generic pricing limits broad-based value expansion, making volume, supply efficiency, qualification and differentiated grades important areas of commercial focus.

Competitive Landscape

• Dr. Reddy's Laboratories Limited — Maintains a broad montelukast sodium regulatory-file portfolio, including U.S., European, Canadian, Chinese and Japanese filings, with additional Japan and Benin DMF activity disclosed in 2025.

• Aarti Pharmalabs Limited — Lists montelukast sodium within its anti-asthmatic API portfolio.

• Laurus Labs Limited — Has documented commercial-scale montelukast manufacturing through its Indian production base.

• Dr. Reddy's Laboratories Limited — Its multi-market regulatory documentation illustrates the importance of geographic filing breadth for global generic API supply.

• Aarti Pharmalabs Limited — Its participation in the anti-asthmatic API portfolio reflects the role of Indian suppliers in merchant API manufacturing.

View the full report: https://www.intelmarketresearch.com/montelukast-sodium-api-64496

Frequently Asked Questions

Q: What is the Montelukast Sodium API Market size and forecast?
A: The market was valued at USD 96.0 million in 2025, is estimated at USD 98.6 million in 2026 and is projected to reach USD 126.0 million by 2034 at a 3.1% CAGR during 2026–2034.

Q: Which region leads the Montelukast Sodium API Market?
A: North America is the largest regional market by value in 2025, while Asia-Pacific is strategically important for both API manufacturing and demand growth.

Q: What is the leading application?
A: Asthma Maintenance represents the principal application and demand pool for montelukast sodium API. Exercise-Induced Bronchoconstriction and Allergic Rhinitis are also covered.

What Does the Full Report Cover?

The full Montelukast Sodium API Market study provides market sizing and forecasting from the 2025 base year through 2034, with detailed analysis by supply type and application. Coverage includes Merchant API and Captive API, along with Asthma Maintenance, Exercise-Induced Bronchoconstriction and Allergic Rhinitis. The report evaluates North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with selected country-level indicators. It also examines supplier qualification, manufacturing capabilities, regulatory positioning, procurement dynamics, pricing pressure, safety considerations, quality risks and supply-chain resilience. Additional coverage addresses DMF/CEP readiness, impurity control, manufacturing geography, specialized grades, dosage-form requirements and recent regulatory developments affecting the market.

View the complete report: https://www.intelmarketresearch.com/montelukast-sodium-api-64496

Download the free sample: https://www.intelmarketresearch.com/download-free-sample/64496/montelukast-sodium-api

Related Reports

The supplied Montelukast Sodium API report page does not provide specific related-report URLs. To comply with the source-only requirement, no unverified related-report links have been added.

About Intel Market Research

Intel Market Research is a provider of strategic market intelligence covering market sizing, forecasts, segmentation, competitive intelligence and regional analysis. Its research reports are designed to provide structured industry information for businesses, analysts and decision-makers evaluating market dynamics, supply landscapes and competitive developments.

Contact Details

Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321